<DOC>
	<DOCNO>NCT00253721</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth tumor cell , either kill cell stop divide . Giving drug directly artery around tumor may kill tumor cell . Mannitol may open blood vessel around brain [ Blood-Brain Barrier Disruption ( BBBD ) ] allow melphalan carry directly brain tumor . Giving melphalan together BBBD may effective treatment central nervous system cancer . PURPOSE : This phase I trial study side effect best dose melphalan give together mannitol treat patient central nervous system cancer .</brief_summary>
	<brief_title>Melphalan With BBBD Treating Patients With Brain Malignancies</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose intra-arterial melphalan give combination BBBD patient primary metastatic central nervous system ( CNS ) malignancy . - Determine toxic effect melphalan give BBBD patient . - Determine , preliminarily , efficacy regimen patient . OUTLINE : This dose-escalation study melphalan . Patients receive intra-arterial mannitol BBBD follow intra-arterial melphalan 10 minute day 1 2* . Treatment repeat every 4 week 12 monthly course absence disease progression unacceptable toxicity . NOTE : *Patients gliomas localize posterior circulation ( i.e. , brain stem glioma ) receive melphalan day 1 . Cohorts 3-6 patient receive escalate dos melphalan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study therapy , patient follow every 3 month 1 year ; every 6 month next 2 year ; annually . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>INCLUSION CRITERIA : Signed write informed consent form accordance institutional guideline Histologically confirm primary metastatic CNS malignancy ( Patients metastatic disease must histological confirmation primary cancer AND confirmation surgical specimen , cerebrospinal fluid cytology , elevate tumor marker , clinical evidence CNS involvement ) Single multiple cerebellar cerebral cortex lesion allow Life expectancy least 60 day Radiographically evaluable disease MRI CT scan Age 18 year old At least 28 day since prior radiotherapy ( systemic , cranial , and/or spinal ) At least 28 day since prior chemotherapy ( 42 day nitrosoureas ) Adequate cardiac pulmonary function tolerate general anesthesia Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Other tumor mass spinal cord allow provide radiographic clinical evidence spinal cord block Available followup least one year follow completion treatment Fertile patient must use effective contraception 2 month prior , , 3 month study participation Pretreatment lab test within 14 day prior initiation treatment : White blood cell count ( WBC ) &gt; 2,500/mm^3 Absolute granulocyte count &gt; 1,200/mm^3 Platelet count &gt; 100,000/mm^3 Hematocrit &gt; 30 % ( transfusion allow ) Bilirubin ≤ 2 time upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ≤ 3 time ULN Creatinine ≤ 2 time ULN Subjects history smoking emphysema require diffuse capacity lung carbon monoxide ( DLCO ) ≥ 80 % predict value age Histological section submit pathology review EXCLUSION CRITERIA : Radiographic evidence excessive intracranial mass effect and/or spinal block Known hypersensitivity intolerance melphalan NCI CTC Grade 3 great baseline neurologic symptom Immunologically compromise ( Concurrent corticosteroid tumor edema allow ) Unable tolerate general anesthesia Pregnant , positive human chorionic gonadotropin ( HCG ) test , lactate HIV positive Receiving concurrent radiotherapy immunotherapy Serious illness would preclude study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult pineoblastoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
</DOC>